A Comparison of QTc Intervals in Alcohol Withdrawal Patients Versus Acute Coronary Syndrome Patients

Chu, Timothy R.; Azevedo, Keith; Ernst, Amy A.; Sarangarm, Dusadee; Weiss, Steven J.

doi:10.14423/smj.0000000000000674

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences in the definition of QT prolongation and correction methods precluded indirect analysis of comparative safety between antidepressants. Primary studies did not evaluate factors that increase susceptibility to QT prolongation and torsades de pointes, including electrolyte disorders, chronic inflammation, baseline cardiovascular disease, comorbidities, or concomitant medications [118][119][120]. The evidence is lacking regarding interaction between antidepressant use with clinical and genetic risk factors for torsade de pointes [121].…”

Section: Discussionmentioning

confidence: 99%

Effects of antidepressants on QT interval in people with mental disorders

Aronow¹,

Shamliyan²

2020

aoms

View full text Add to dashboard Cite

Introduction: Drug-induced QT prolongation is associated with higher cardiovascular mortality. Material and methods: We conducted a protocol-based comprehensive review of antidepressant-induced QT prolongation in people with mental disorders.Results: Based on findings from 47 published randomized controlled trials (RCTs), 3 unpublished RCTs, 14 observational studies, 662 case reports of torsades de pointes, and 168 cases of QT prolongation, we conclude that all antidepressants should be used only with licensed doses, and that all patients receiving antidepressants require monitoring of QT prolongation and clinical symptoms of cardiac arrhythmias. Large observational studies suggest increased mortality associated with all antidepressants (

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of antidepressants on QT interval in people with mental disorders

Aronow¹,

Shamliyan²

2020

aoms

View full text Add to dashboard Cite

show abstract

A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers

Morice

Baker

Patel

et al. 2021

Sci Rep

View full text Add to dashboard Cite

PT150, a novel competitive glucocorticoid receptor (GR) antagonist, has proven safe in animal models, healthy volunteers, and people with depression. Our study is the first to investigate PT150’s safety with alcohol use. The primary objective of this study was to evaluate pharmacodynamic interactions between ethanol and PT150 in healthy subjects. This single-site, Phase I pilot trial consisted of community-recruited, healthy, alcohol-experienced participants aged 21–64 years. Of 32 participants screened, 11 were enrolled and randomized, one of which withdrew before intervention. PT150 (900 mg/day) was administered orally to all participants for five days. All participants received two beverage challenges on Day 1 (before PT150 administration) and Day 5 (after PT150 administration). On challenge days, they received both alcohol (16% ethanol) and placebo (1% ethanol) beverages in random order. Primary outcomes included breath alcohol level, blood pressure, heart rate, adverse events, and electrocardiogram changes. There were no statistically significant differences in vital signs or estimated blood alcohol concentrations between PT150 non-exposed and exposed groups during the ethanol challenge. There were no clinically significant abnormal electrocardiograms or serious adverse events. These data show that administration of PT150 with concurrent alcohol use is safe and well-tolerated. This study supports a future pharmacokinetic interaction study between PT150 and alcohol.Trial Registration ClinicalTrials.gov Identifier: NCT03548714.

show abstract

A Comparison of QTc Intervals in Alcohol Withdrawal Patients Versus Acute Coronary Syndrome Patients

Cited by 2 publications

References 20 publications

Effects of antidepressants on QT interval in people with mental disorders

Effects of antidepressants on QT interval in people with mental disorders

A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers

Contact Info

Product

Resources

About